Voruciclib
Voruciclib is an orally active and selective CDK inhibitor with Ki values of 0.626 nM-9.1 nM. Voruciclib potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL) [1].
Product Specifications
CAS Number
1000023-04-0
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/voruciclib.html
Purity
99.77
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1C=C(C2=CC=C(C(F)(F)F)C=C2Cl)OC3=C([C@H]4[C@H](CO)N(C)CC4)C(O)=CC(O)=C13
Molecular Formula
C22H19ClF3NO5
Molecular Weight
469.84
Precautions
H302, H315, H319, H335
References & Citations
[1]Dey J, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci Rep. 2017 Dec 21;7 (1) :18007.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
CDK1; CDK4; CDK6; CDK9
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS2040874-01 0.1 mL
Cy3-Linked Monoclonal Antibody to Galectin 7 (GAL7)
Sign In for Pricing
View Details MBS2040874-02 0.2 mL
Cy3-Linked Monoclonal Antibody to Galectin 7 (GAL7)
Sign In for Pricing
View Details